BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA) r
Understanding commercial and market access risks and opportunities at an early stage in biopharmaceutical product development is essential for optimizing commercial success.
At Frontiers Health 2022, pharmaphorum Editor in Chief Jonah Comstock sat down with Matthew Holt, the founder and publisher of the Health Care Blog and a long-time self-described “digital health cu
